EP1144434A2 - Combinatorial process for preparing polyamines - Google Patents
Combinatorial process for preparing polyaminesInfo
- Publication number
- EP1144434A2 EP1144434A2 EP99936759A EP99936759A EP1144434A2 EP 1144434 A2 EP1144434 A2 EP 1144434A2 EP 99936759 A EP99936759 A EP 99936759A EP 99936759 A EP99936759 A EP 99936759A EP 1144434 A2 EP1144434 A2 EP 1144434A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- moiety
- formula
- process according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
Definitions
- This invention relates to a process for preparing polyamines and particularly, although not exclusively, relates to a solid phase process and/or a process which can readily be used in a combinatorial or parallel array technique-
- polyamine amide compounds have shown neurological activity and have glutamate receptor antagonist activity. Hitherto, they have been considered for use in the treatment of neurological disorders such as Alzheimer's disease, Huntingdon's chorea, stroke and brain trauma.
- a process for preparing a polyamine compound which includes a step (a) of treating a compound which incorporates a moiety of formula:
- SS represents a solid support and linking means for linking the group -NR- of moiety I to the support
- R represents a hydrogen atom or an optionally-substituted alkyl or aryl group
- R 1 represents a hydrogen atom or an optionally-substituted alkyl or aryl group
- R b and R c each independently represents an optionally-substituted alkylene or alkenylene group
- L represents a leaving group.
- any group may be substituted by one or more substituents.
- it may be substituted by up to 4, preferably up to 3, more preferably up to 2, especially up to 1 substituent.
- optional substituents may be selected from halogen (preferably fluorine, chlorine or bromine) atoms and optionally substituted, preferably unsubstituted, alkyl, acyl, aryl, nitro, cyano, alkoxy, alkoxyalkyl, hydroxy, amino, alkylamino (including dialkylamino) , sulphinyl, alkylsulphinyl, carbamoyl (including alkylcarbamoyl and dialkylcarbamoyl) , sulphonyl, alkylsulphonyl, sulphonate, amido, alkylamido, alkoxycarbonyl, halocarbonyl (especially chlorocarbonyl) , haloalkoxy, and haloalkyl (especially fluoroalkyl or chloroalkyl) , groups.
- halogen preferably fluorine, chlorine or bromine
- an alkyl, alkenyl, alkylene or alkenylene group may have up to 12, suitably up to 10, preferably up to 8, more preferably up to 6, especially up to 4, carbon atoms.
- an aryl group is suitably an aromatic or heteroaromatic group which preferably has 6 to 10 ring atoms and, more preferably, has 6 or 10 ring atoms.
- aromatic groups include phenyl, 1-naphthyl and 2-naphthyl groups of which the phenyl group is preferred.
- Heteroaromatic groups may include one or more 0, N or S atoms or combinations thereof.
- the process suitably produces a compound which incorporates a moiety: WO 00/35941 _- ⁇ 4 _- PCT/GB99/01719
- R represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl group. More preferably, R represent a hydrogen atom.
- R b and R c may independently have up to 10, suitably up to 8, preferably up to 6, more preferably up to 4, carbon atoms in a straight chain.
- R b and R c may have the same number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds moieties produced in downstream processes) may be symmetrical polyamines.
- R b and R c may have a different number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds/moieties produced in downstream processes) may be unsymmetrical polyamines.
- Unsymmetrical polyamines can be quite difficult to prepare by known processes; however, the process described herein can relatively easily be used to make such compounds.
- R and R c independently have 3 or 4 carbon atoms in a straight chain. More preferably, R c has 4 carbon atoms and R b has 3 carbon atoms in a straight chain. R b and R c may independently be optionally substituted by 1 or 2 optionally-substituted, preferably unsubstituted, alkyl groups, wherein each alkyl group suitably has 1 to 3 carbon atoms.
- R 1 suitably represents a hydrogen atom or a C ⁇ - ⁇ o, preferably C ⁇ - 8 , more preferably C ⁇ _ 6 , especially C ⁇ - 4 , alkyl group or an aryl group, said alkyl or aryl group being optionally-substituted, preferably by one or more substituents selected from halogen atoms, amino groups, alkylamino groups, dialkylamino groups, cyano groups, hydroxy groups, alkyl groups (except when the substituted group is alkyl) , aryl groups, carbamoyl groups, alkylcarbamoyl groups, dialkylcarbamoyl groups and carboxy groups and esters thereof.
- R 1 represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl or aryl group.
- R 1 represents a hydrogen atom or an optionally-substituted alkyl group.
- P 1 represents a protecting/activating group.
- P 1 is preferably an electron-withdrawing group. It is preferably adapted to increase the acidity of the hydrogen atom of the group -NHP 1 .
- P 1 preferably forms a sulphonamide group with moiety I.
- P 1 preferably represents a moiety: -SO2-X 1 V
- X 1 represents an optionally-substituted aryl, especially phenyl, group.
- Said optionally-substituted aryl group may include one or more substituents.
- Preferred substituents are electron-withdrawing groups.
- a nitro group is a preferred optional substituent.
- a 4- nitro or a 2,4-nitro is especially preferred.
- X 1 represents a di-nitrophenyl group.
- moieties I and II The mechanism of the reaction of moieties I and II is believed to involve attack of the nucleophilic nitrogen atom of moiety -NH- of moiety I with a carbon atom adjacent to leaving group L in moiety II.
- L is preferably an electron-withdrawing group. Consequently, the leaving group L is displaced.
- L may need to be activated to act as a leaving group in the reaction.
- L may be any leaving group which may be electronegative and/or be capable of functioning in the mechanism referred to.
- L may be a halogen atom, preferably a bromine or chlorine atom, especially a bromine atom, or a hydroxy group. The ability of the hydroxy group to act as a leaving group may be caused and/or enhanced by other reagents used in the reaction.
- P 2 NR X -R b -L VI wherein P 2 represents a protecting group.
- Preferred protecting groups include N-l- (4, 4-dimethyl-2, 6- dioxocyclohex-1-ylidene) ethyl and Triethlsilyloxycarbonyl (TEOC) . The former is preferred.
- SS represents a solid support resin which includes linking means.
- Said linking means may include a -O-CO- moiety, the carboxy end of which is suitably bonded to the nitrogen atom of the moiety -NR- of moiety I.
- the alkoxy end of the -0-CO- moiety may be bonded to the resin by suitable means which is preferably an alkylene group, especially a -CH 2 - group.
- Said solid support resin may be any suitable resin, for example a polystyrene resin.
- the linking means is a Wang linker.
- Step (a) swollen resin of formula I (which may suitably be swollen in anhydrous tetrahydrofuran) , triphenylphosphine and a said compound which incorporates moiety II (especially compound VI) may be stirred together and, subsequently, a coupling agent, suitably diethylazodicarboxylate, is added, slowly. The mixture may be stirred for about 12 hours, filtered, washed and dried.
- the product of the reaction suitably incorporates moiety III and is suitably protected by groups P 2 and P 1 and is, therefore, of formula:
- Said compound VI may be prepared by a reaction known to a person skilled in the art, wherein P 2 is a protecting group.
- Said compound IV may be prepared in a step (-b) which comprises reaction of a compound of general formula:
- reaction is preferably carried out in the presence of a base, for example 2,6-lutidine and in an organic solvent.
- Said compound of formula VIII may be prepared in a step (-c) by reaction of a compound of formula
- L 3 represents a leaving group which may include an imidazole moiety.
- Compound VII and/or said compound incorporating moiety II can readily be derivatised to produce a wide range of compounds, suitably in a parallel array or combinatorial chemistry technique.
- compound VII and/or said compound incorporating moiety III may be treated with a further compound which incorporates a moiety of formula II (which moiety may include R 1 , R b and L which are the same as or different to such groups used in Step (a) ) as described above thereby to prepare a compound which incorporates the moiety
- R b (2), R x (2) and P 2 (2) may be any group described herein for R b , R 1 and P 2 respectively except that they may be the same or different to groups R b and R 1 used in Step (a) and P 2 as described above.
- said compound of formula VII may be reacted to remove P 1 and replace it with, for example another protecting group (e.g. Boc) and P 2 may be removed and replaced with a protecting/activating group of type P 1 discussed above.
- the derivatised compound VII prepared may then be treated, for example with a structure of formula:
- the derivatisation of the first embodiment may be further repeated to add successive groups -NR 1 (3) -R b (3) - etc.
- Compound VII may be derivatized by a range of compounds, for example amino acids, may be coupled to moiety -NR 1 - (or -NR 1 (2), -NR 1 (3) if provided) , thereby replacing protecting group P 2 and, in turn, other compounds, for example further amino acids, may be coupled to said compounds initially coupled to moiety -NR 1 - (or -NR 1 (2), -NR 1 (3), if provided) and/or derivatisation reactions effected. Further coupling reactions may also be effected by techniques known to those skilled in the art.
- a suitably deprotected compound VII and/or said compound incorporating moiety III may be treated with a first reagent (which may be protected) to replace group P 2 in compound VII with a residue of said first reagent.
- the product (or a derivative), suitably deprotected may be treated with a second reagent (which may be protected) so that said second reagent becomes bonded to a said residue of said second reagent.
- Such treatments may be repeated to react further reagents with the derivative of compound VII.
- said first reagent is di-functional.
- Said first reagent preferably includes an aryl group (or a precursor thereof) .
- Said first reagent preferably includes an amine group (or a precursor thereof) .
- said first reagent (and a or any subsequent reagent) is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) .
- said second reagent is di-functional.
- Said second reagent preferably includes an aryl group (or a precursor thereof) .
- Said second reagent preferably includes an amine group (or a precursor thereof) .
- said second reagent is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) .
- Further reagents which may be reacted with said second reagent may have any feature of said second reagent as described above.
- step (b) said compound of formula VII may be reacted in a step (b) to substitute the group P 1 with another group which may be another protecting group P 3 or an electrophilic reagent.
- Group P 3 may be an acyl, -Boc, alkyl, or sulphonyl group.
- the product of step (b) may be a compound of formula
- Step (c) may involve reaction in hydrazine and an organic solvent or may involve any suitable deprotection reaction.
- a compound may be coupled to the free -NH 2 group of compound XI.
- an amino acid suitably an amino acid which is protected by a protecting group orthogonal to the group binding portions of compound X to the solid support of SS, such as an Fmoc protected amino acid (i.e. "Fmoc AA"
- an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 1 may be coupled to said group.
- other compounds for example other amino acids, may be coupled, for example to the aforementioned amino acid, in order to produce more complex compounds using procedures know to those skilled in the art.
- an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 2 may be coupled.
- the desired compound prepared may be cleaved from the resin and/or optionally derivatised as may be desired.
- Such a compound may incorporate a moiety
- a 1 is a substituent group which may comprise one or more optionally derivatised amino acid residues or is a salt of the aforementioned compound.
- such a compound may be of formula
- R, R c , R b and R 1 are as described in any statement herein;
- W is a hydrogen atom or an optionally- substituted, preferably unsubstituted, alkyl or aryl group;
- Z is an amino acid residue, especially an aromatic amino acid residue;
- n is zero or a positive integer, preferably in the range 0-10, more preferably 0-4, especially 0 to 1;
- R 2 and R 3 are the same or different from each other and each represents a hydrogen atom or a group of formula R 6 , R 6 CO-, R 6 OCO- or R 6 NHCO- where R 6 represents an optionally-substituted alkyl group, suitably a Ci-io, preferably a Ci-e, more preferably a Ci- ⁇ , especially a C ⁇ - , alkyl group, or an optionally- substituted aryl group, wherein preferred optional substituents of said alkyl and aryl groups are selected from halogen atoms, amino groups
- a process for preparing a plurality of different polyamine compounds which includes a step of:
- a library of compounds prepared in a process according to said second aspect.
- the resin was again swollen in dichloromethane (1.0 ml), and di-t-butyl dicarbonate (10 equivalents, 0.3 mmol, 33 mg) and N,N-dimethylaminopyridine (5 mol%, 0.0015 mmol, 0.2 mg) were added, and the mixture was stirred for 16 hours. The resin was then filtered and washed (dimethylformamide, methanol, dichloromethane) , and then dried in vacuo.
- the resin was then stirred in 2% hydrazine hydrate/dimethylformamide (1.0 ml) for 1 hour and then washed (dimethylformamide, methanol, dichloromethane) , after which it was dried in vacuo.
- Boc-Arg(Pbf) -OH (4 equivalents, 0.12 mmol, 63 mg)
- TBTU (4 equivalents, 0.12 mmol, 39 mg)
- diisopropylethylamine 8 equivalents, 0.48 mmol, 62 mg
- the Dde protected aminoalcohol was prepared as follows: To a solution of 3-amino-l-propanol (1.5 g, 20 mmol) in ethanol was added 2-acetyl dimedone (1.1 equivalents, 22 mmol, 4.0 g) and the mixture was heated to
- the resin was again swollen in DCM (1.0 ml) and di-t- butyldicarbonate (10 eq, 0.3 mmol) and N,N- dimethylaminopyridine (5 mol%, 0.0015 mmol) added and the mixture stirred for 16 hours.
- the resin was then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
- the resin was then stirred in 2% hydrazine hydrate/DMF (1.0 ml) for 1 hour then washed (DMF, MeOH, DCM) and dried in vacuo.
- Fmoc AA1 The Fmoc derivatives of the amino acids shown in Summary 1 (wherein residues thereof are destined to become Portion 1 in the polyamines) were prepared (hereinafter referred to, generally, as "Fmoc AA1") . Then, Fmoc AA1 (4 eq, 0.12 mmol), TBTU (4 eq, 0.12 mmol) and diisopropylethylamine (8 eq, 0.48 mmol) were dissolved in anhydrous DMF (1.0 ml) and the mixture added to the resin. The whole was then stirred for 12 hours then filtered and washed (DMF, MeOH, DCM) and dried in vacuo.
- Boc AA eq, 0.12 mmol
- TBTU eq, 0.12 mmol
- diisopropylethylamine 8 eq, 0.48 mmol
- amino acid residues incorporated into compound E-I comprise the amino acids shown in Summary I and II but excluding hydrogen atoms from the -NH 2 and -C0 2 H groups.
- Table 1 summarises a 4, 4-polyamine library prepared - that is, a library wherein n and m represent 4; the left column in the table details respective Portion l's (identified by their letters in Summary 1) used to prepare the compounds; and the top row details respective Portion 2's (identified by their numbers in Summary 2) used to prepare the compounds.
- Table 2 summarises a 3, 4-polyamine library - that is, wherein n represents 3 and m represents 4 with Portions 1 and 2 being identified as before.
- each box in the table represents a particular compound prepared and the Mass Spec (ES + ) and HPLC Retention Time in minutes are provided in each box (where available) .
- TEOC may be used.
- Derivatives of the amines prepared in Examples 1 and 2 may be prepared by reaction with a compound having an electrophilic specie such as an acid chloride, sulphonyl chloride etc.
- the starting material of Step 5 may be acylated, instead of using di-t- butyldicarbonate to give a Boc protecting group.
- Acylation may be carried out using a standard technique, using an acid chloride or another activated acid, to produce peptidomimetics .
- Sulphonyl chlorides may be used to sulphonylate amine groups to produce derivatives.
- Step 4 in Example 4 may be repeated more than once in order to add further moieties -NH-(CH 2 ) n - to the polyamine chain.
- the Dde group may be removed and the resultant free amine group re-sulphonated in a process analogous to that described in Step 3.
- the re-sulphonated product may then be treated with a Dde-protected amine alcohol in a process analogous to that described in Step 4.
- Step 5 may be repeated.
- further moieties -NH-(CH 2 ) n - may be added in the manner described or Step 6 and subsequent steps described may be carried out.
- the product of Step 6 may be of formula
- N is an integer of 1 or greater and wherein n may be the same or different for each repeat unit N.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WOPCT/GB98/03775 | 1998-12-16 | ||
PCT/GB1998/003775 WO1999031049A1 (en) | 1997-12-16 | 1998-12-16 | Neuroprotective agents |
PCT/GB1999/001719 WO2000035941A2 (en) | 1998-12-16 | 1999-06-16 | Combinatorial process for preparing polyamines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1144434A2 true EP1144434A2 (en) | 2001-10-17 |
EP1144434A3 EP1144434A3 (en) | 2002-05-29 |
Family
ID=10827438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99936759A Withdrawn EP1144434A3 (en) | 1998-12-16 | 1999-06-16 | Combinatorial process for preparing polyamines |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1144434A3 (en) |
CA (1) | CA2355880A1 (en) |
WO (1) | WO2000035941A2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU758570B2 (en) * | 1997-07-15 | 2003-03-27 | Mediquest Therapeutics, Inc. | Novel polyamine analogues as therapeutic and diagnostic agents |
-
1999
- 1999-06-16 CA CA002355880A patent/CA2355880A1/en not_active Abandoned
- 1999-06-16 EP EP99936759A patent/EP1144434A3/en not_active Withdrawn
- 1999-06-16 WO PCT/GB1999/001719 patent/WO2000035941A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0035941A3 * |
Also Published As
Publication number | Publication date |
---|---|
CA2355880A1 (en) | 2000-06-22 |
EP1144434A3 (en) | 2002-05-29 |
WO2000035941A2 (en) | 2000-06-22 |
WO2000035941A3 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2715233C2 (en) | Method of producing nitrogen mustard derivatives | |
Myers et al. | Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors | |
CN114040920A (en) | Method for producing peptide compound, protecting group-forming reagent, and fused polycyclic aromatic hydrocarbon compound | |
US7067698B2 (en) | Bi-directional synthesis of oligoguanidine transport agents | |
WO2021177336A1 (en) | Peptide and cell membrane permeation agent | |
AU2006318131B2 (en) | Compounds for the inhibition of apoptosis | |
Ricardo et al. | On the scope of the double Ugi multicomponent stapling to produce helical peptides | |
Vandersteen et al. | Liquid-phase combinatorial synthesis: in search of small-molecule enzyme mimics | |
US6872825B2 (en) | Peptide β-turn mimetic compounds and processes for making them | |
EP1144434A2 (en) | Combinatorial process for preparing polyamines | |
CA2922332A1 (en) | A photolabile linker for the solid-phase synthesis of hydrazides and pyranopyrazoles | |
Busnel et al. | Synthesis of Fmoc-protected aza-β3-amino acids via reductive amination of glyoxylic acid | |
JP5947821B2 (en) | Method for producing cereulide and derivatives thereof, intermediate for producing cereulide and cereulide derivatives | |
Plöger et al. | Improved Large‐Scale Liquid‐Phase Synthesis and High‐Temperature NMR Characterization of Short (F‐) PNAs | |
TWI772159B (en) | Method of synthesizing dendrimeric amphiphile | |
Ferrer‐Gago et al. | Synthesis of C‐terminal glycine‐rich o‐aminoanilide peptides without overacylation for use in benzotriazole‐mediated native chemical ligation | |
Pinto et al. | Straightforward, racemization-free synthesis of peptides with fairly to very bulky di-and trisubstituted glycines | |
WO2023023889A1 (en) | Method of synthesizing dendrimeric amphiphile | |
US8124756B2 (en) | Method of preparing 5′-amino-linker oligonucleotides derivatives and analogous 5′-labeled-linker oligonucleotides therefrom | |
CZ20022110A3 (en) | Peptide beta-rotating mimetic compounds and process of their preparation | |
EP4247798A1 (en) | Synthesis of prostate specific membrane antigen (psma) ligands | |
EP4247785A1 (en) | Synthesis of prostate specific membrane antigen (psma) ligands | |
WO2023102255A1 (en) | Peptide-encoded libraries of small molecules for de novo drug discovery | |
US6664410B1 (en) | Solid phase nitrile synthesis | |
Chulin et al. | Synthesis of 10‐and 9‐membered dilactams derived from aspartic and glutamic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010627 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE |
|
XX | Miscellaneous |
Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR. |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050101 |